Incidence and one-year mortality of penile cancer in the Russian Federation. Part 1

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Penile cancer is a rare malignant tumor: its prevalence ranges from 0.1 to 5.9 cases per 100,000 men. This type of cancer is very often left out due to the rarely correctly diagnosed disease and the lack of awareness among the male population about the need to regularly prevent checkups with an urologist. The rates depend significantly on the region, but in less populated regions, morbidity and mortality are significantly lower than in large cities due to the lack of diagnostic measures and the low frequency of treatment in case of clinical symptoms.

Aim. To perform the population-level analysis of temporal trends in the incidence and mortality of penile cancer in the Russian Federation, as well as to evaluate the completeness and quality of case registration for this malignancy. Additionally, patterns of one-year incidence and mortality were examined using data from the population-based cancer registry of the Northwestern Federal District.

Materials and methods. Data were obtained from the International Agency for Research on Cancer, the population-based cancer registry of the Northwestern Federal District of the Russian Federation, and the N. N. Petrov National Medical Research Center of Oncology, Ministry of Health of the Russian Federation (Saint Petersburg). For detailed assessment of epidemiological characteristics, including one-year incidence and mortality among patients with penile cancer, the database of the Northwestern Federal District population-based cancer registry was analyzed. The overall study cohort comprised 2,728 registered cases of penile cancer.

Results and conclusion. From 2000 to 2023, both the absolute number of cases and the age-standardized incidence rate of penile cancer in the Russian Federation demonstrated an increasing trend, with the age-standardized incidence rate rising from 0.54 to 0.98 per 100,000 population. However, since 2019, a declining trend in the age-standardized incidence rate has been observed.

About the authors

V. M. Merabishvili

N. N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia

Email: berkutv91@gmail.com
ORCID iD: 0000-0002-1521-455X
Russian Federation, 68 Leningradskaya St., Pesochnyy, Saint Petersburg 197758

Mariya V. Berkut

N. N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia

Author for correspondence.
Email: berkutv91@gmail.com
ORCID iD: 0000-0002-6276-1716
Russian Federation, 68 Leningradskaya St., Pesochnyy, Saint Petersburg 197758

P. M. Gorlin

N. N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia

Email: berkutv91@gmail.com
ORCID iD: 0009-0008-8245-6234
Russian Federation, 68 Leningradskaya St., Pesochnyy, Saint Petersburg 197758

A. K. Nosov

N. N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia

Email: berkutv91@gmail.com
ORCID iD: 0000-0003-3850-7109
Russian Federation, 68 Leningradskaya St., Pesochnyy, Saint Petersburg 197758

References

  1. Bray F., Colombet M., Aitken J.F. et al. Cancer Incidence in Five Continents. Vol. XII. International Agency for Research on Cancer. Lyon, 2023. Available at: https://ci5.iarc.who.int
  2. Sung H., Ferlay J., Siegel R. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3): 209–49. doi: 10.3322/caac.21660
  3. Malignant tumors in Russia in 2023 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shakhzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2024. 276 p. (In Russ.).
  4. Malignant tumors in Russia in 2010 (morbidity and mortality). Eds.: V.I. Chissov, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena Minzdravsotsrazvitiya Rossii, 2012. 201 p. (In Russ.).
  5. Malignant tumors in Russia in 2015 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2017. 250 p. (In Russ.).
  6. Malignant tumors in Russia in 2019 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, A.O Shachzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2020. 214 p. (In Russ.).
  7. Malignant tumors in Russia in 2020 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2021. 252 p. (In Russ.).
  8. State of oncological care in Russia in 2021. Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shachzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2022. 239 p. (In Russ.).
  9. Merabishvili V.M. Malignant neoplasms in the Northwestern Federal District of Russia (incidence, mortality, data reliability, patient survival). Express Information. Issue 6. Ed.: A.M. Belyaev. Saint Petersburg: Izdatelskiye tekhnologii, 2023. 390 p. (In Russ.).
  10. Merabishvili V.M. Oncological statistics (traditional methods, new information technologies): a guide for doctors. 2nd edn., revised. Part I. Saint Petersburg: IPK “KOSTA”, 2015. 181 p. (In Russ.).
  11. Merabishvili V.M. Oncological statistics (traditional methods, new information technologies): a guide for doctors. 2nd edn., revised. Part II. Saint Petersburg: IPK “KOSTA”, 2015. 181 p. (In Russ.).
  12. Merabishvili V.M. Malignant neoplasms in the Northwestern Federal District of Russia (incidence, mortality, data reliability, patient survival). Express Information. Issue 5. Ed.: A.M. Belyaev, A.M. Shcherbakov. Saint Petersburg: Izdatelskiye tekhnologii, 2020. 176 p. (In Russ.).
  13. Barski D., Georgas E., Gerullis H., Ecke T. Metastatic penile carcinoma - an update on the current diagnosis and treatment options. Cent Eur J Urol 2014;67(2):126–32. doi: 10.5173/ceju.2014.02.art2
  14. Kombe Kombe A.J., Li B., Zahid A. et al. Epidemiology and burden of human papillomavirus and related diseases, molecular pathogenesis, and vaccine evaluation. Front Public Health 2021;8:1003. DOI: 10.3389/ fpubh.2020.552028
  15. Glombik D., Oxelbark A., Sundqvist P. et al. Risk of second HPV-associated cancers in men with penile cancer. Acta Oncologica 2021;60(5):667–71. doi: 10.1080/02 84186x.2021.1885056
  16. Axel E.M., Matveev V.B. Statistics of malignant tumors of urinary and male urogenital organs in Russia and the countries of the former USSR. Onkourologiya = Cancer Urology 2019;15(2):15–24. (In Russ.). doi: 10.17650/1726-9776-2019-15-2-15-24
  17. Varma V.A., Sanchez-Lanier M., Unger E.R. et al. Association of human papillomavirus with penile carcinoma: a study using polymerase chain reaction and in situ hybridization. Human Pathology 1991;22(9):908–13. doi: 10.1016/0046-8177(91)90181-n
  18. Miralles-Guri C., Bruni L., Cubilla A.L. et al. Human papillomavirus prevalence and type distribution in penile carcinoma. J Clin Pathol 2009;62(10):870–8. DOI: 10.1136/ jcp.2008.063149.
  19. Yanagawa N., Osakabe M., Hayashi M. et al. Detection of HPV-DNA, p53alterations, and methylation in penile squamous cell carcinoma in Japanese men. Pathol Int 2008;58(8):477.
  20. Gu W., Zhang P., Zhang G. et al. Importance of HPV in chinese penile cancer: a contemporary multicenter study. Front Oncol 2020;10. DOI: 10.3389/ fonc.2020.01521
  21. Brouwer O.R., Albersen M., Parnham A. et al. European Association of Urology-American Society of Clinical Oncology collaborative guideline on penile cancer: 2023 update. Eur Urol 2023;83(6):548–60. doi: 10.1016/j.eururo.2023.02.027
  22. Briko N.I., Lopukhov P.D., Kaprin A.D. et al. HPV-associated lesions in the Russian Federation: assessment of the problem’s state. Sovremennaya onkologiya = Modern Oncology 2019;21(1):45–50. (In Russ.). doi: 10.26442/18151434.2019.190199

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2026 ABV-Press

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36986 от  21.07.2009.